Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Clarke, N W, Ali, A, Ingleby, F C, Hoyle, A, Amos, C L, Attard, G, Brawley, C D, Calvert, J, Chowdhury, S, Cook, A, Cross, W, Dearnaley, D P, Douis, H, Gilbert, D, Gillessen, S, Jones, R J, Langley, R E, MacNair, A, Malik, Z, Mason, M D, Matheson, D, Millman, R, Parker, C C, Ritchie, A W S, Rush, H, Russell, J M, Brown, J, Beesley, S, Birtle, A, Capaldi, L, Gale, J, Gibbs, S, Lydon, A, Nikapota, A, Omlin, A, O'Sullivan, J M, Parikh, O, Protheroe, A, Rudman, S, Srihari, N N, Simms, M, Tanguay, J S, Tolan, S, Wagstaff, J, Wallace, J, Wylie, J, Zarkar, A, Sydes, M R, Parmar, M K B and James, N D (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of oncology : official journal of the European Society for Medical Oncology. ISSN 1569-8041.

Full text not available from this repository.
Official URL: https://academic.oup.com/annonc/article/doi/10.109...

Abstract

BACKGROUND

STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients.

METHODS

We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional.

RESULTS

Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression).

CONCLUSIONS

The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.

Item Type: Article
Subjects: QY Clinical pathology
QZ Pathology. Oncology
Divisions: Clinical Support > Radiology
Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 07 Oct 2019 13:49
Last Modified: 07 Oct 2019 13:49
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2455

Actions (login required)

View Item View Item